Bexion Pharmaceuticals received Orphan Drug Designation for its novel drug, BXQ-350 for the treatment of patients with glioblastoma multiforme. The drug has shown activity in over 60 different cancer cell lines, and is toxic to cancer cells, only.The nanovesicals bypass the blood brain barrier. Continue reading
Researchers at the University of North Carolina have been developing a chemotherapy drug treatment utilizing iontophoresis specifically for prostate and breast cancer. Continue reading
Can-Fite BioPharma announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. The study will enroll 78 patients with refractory advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. Patients will receive 25 mg of CF102 orally twice a day; the endpoint will be overall survival between those receiving CF102 versus placebo. Continue reading
Researchers at St. Jude Children’s hospital have identified the population of white blood cells that tumors use to propagate their growth AND to suppress the immune system. Continue reading
CANCER RESEARCH UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells – paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool next week. This process is known as apoptosis. Continue reading
The combination of Herceptin plus pan-HER (EGFR and Her 2 an 4) kinase inhibitor neratinib resulted in a 33% improvement in progression free survival versus Herceptin alone in breast cancer patients. Rituxan combined with idelalisib, PI3K inhibitor, resulted in a near doubling of progression-free survival at 24 weeks versus Rituxan, alone in patients with Chronic Lymphocytic Leukemia, non-Hodgkin’s Lymphoma, and small cell lymphoma. The news for neratinib tripled the valuation of Puma Biotechnology, while the FDA granted approval of Gilead’s drug Zydelig (idelalisib). Continue reading